Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 12/20 | 0.80 |
| ▸ | CACNA1I | Q9P0X4 | 9/20 | 0.80 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275690 | 0.94 | CACNA1H (0.86) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 | |
| SCHEMBL4285572 | 0.92 | CACNA1I (0.78) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 | |
| SCHEMBL4270972 | 0.91 | CACNA1I (0.67) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 | |
| SCHEMBL19113162 | 0.89 | CACNA1I (0.65) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 | |
| SCHEMBL8371285 | 0.89 | CACNA1H (0.78) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 | |
| Ulixacaltamide SCHEMBL30235364 | 0.89 | CACNA1H (1.00) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 | |
| Ulixacaltamide SCHEMBL4271563 | 0.89 | CACNA1H (1.00) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 | |
| Ulixacaltamide SCHEMBL25213995 | 0.88 | CACNA1H (0.98) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 | |
| SCHEMBL4274643 | 0.88 | CACNA1H (0.77) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 | |
| SCHEMBL14770281 | 0.88 | CACNA1I (0.88) | CACNA1HCACNA1ICACNA1GKCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192687-A1 | T-TYPE CALCIUM CHANNEL MODULATORS COMPRISING AN AZASPIROHEPTANE CORE AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230192612-A1 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PRECISION MEDICINES, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230165847-A1 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| US-11649207-B2 | Formulations of T-type calcium channel modulators and methods of use thereof | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3189839-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | PRAXIS PREC MEDICINES INC (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3189839-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | PRAXIS PREC MEDICINES INC (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-2300007-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TARO PHARMACEUTICALS INC (CA) | 2018-04-18 | — | — | EP | disclosed |
| EP-2300007-B1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TARO PHARMACEUTICALS INC (CA) | 2018-04-18 | — | — | EP | disclosed |
| EP-3189839-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Taro Pharmaceuticals Inc. (CA) | 2017-07-12 | — | — | EP | disclosed |
| EP-3189839-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Taro Pharmaceuticals Inc. (CA) | 2017-07-12 | — | — | EP | disclosed |
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| WO-2009146540-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2009-12-10 | — | — | WO | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1H 2/4885CACNA1I 4/4885CACNA1G 1/4885 |
| US-20230192612-A1 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CACNA1G, CACNA1H, CACNA1I | CACNA1H 2/4885CACNA1I 3/4885CACNA1G 1/4885 |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | CACNA1H 2/4885CACNA1I 4/4885CACNA1G 1/4885 |
| US-11649207-B2 | Formulations of T-type calcium channel modulators and methods of use thereof | CACNA1G, CACNA1H, CACNA1I | CACNA1H 2/4885CACNA1I 3/4885CACNA1G 1/4885 |
| US-20230165847-A1 | METHODS OF USE OF T-TYPE CALCIUM CHANNEL MODULATORS | CACNA1G, CACNA1H, CACNA1I | CACNA1H 2/4885CACNA1I 3/4885CACNA1G 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.